Pacific Biosciences of California Inc. [NASDAQ: PACB] price surged by 3.78 percent to reach at $0.33. The company report on March 14, 2023 that PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Paraphase Enables Researchers to Analyze Genes That are Critically Relevant but Hard to Genotype.
PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy. The new computational tool, named “Paraphase,” enables variant calling, copy number analysis and phasing by identifying the full gene sequence of each of the haplotypes for all genes and pseudogenes of the same gene family. Many medically relevant genes fall into segmental duplications and thus have highly similar gene family members or pseudogenes. The sequence similarity often leads to error prone read alignment and variant calling.
A sum of 4515840 shares traded at recent session while its average daily volume was at 4.23M shares. Pacific Biosciences of California Inc. shares reached a high of $9.08 and dropped to a low of $8.41 until finishing in the latest session at $9.06.
The one-year PACB stock forecast points to a potential upside of 25.25. The average equity rating for PACB stock is currently 2.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Pacific Biosciences of California Inc. [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $12.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 02, 2023. The new note on the price target was released on January 20, 2023, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $12, while Scotiabank analysts kept a Sector Outperform rating on PACB stock. On January 21, 2022, analysts decreased their price target for PACB shares from 62 to 31.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 0.68, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 18.44. The Price to Book ratio for the last quarter was 3.64, with the Price to Cash per share for the same quarter was set at 2.96.
PACB Stock Performance Analysis:
Pacific Biosciences of California Inc. [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.80. With this latest performance, PACB shares dropped by -11.70% in over the last four-week period, additionally plugging by 47.56% over the last 6 months – not to mention a rise of 7.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 45.64, with the RSI for the last a single of trading hit 47.65, and the three-weeks RSI is set at 46.00 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 10.09, while it was recorded at 8.72 for the last single week of trading, and 7.63 for the last 200 days.
Insight into Pacific Biosciences of California Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -237.58 and a Gross Margin at +38.08. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at -244.92.
Return on Equity for this stock declined to -46.42, with Return on Assets sitting at -16.65.
Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.20.
PACB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.
Pacific Biosciences of California Inc. [PACB] Insider Position Details
There are presently around $2,059 million, or 88.90% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 25,691,681, which is approximately -10.459% of the company’s market cap and around 0.80% of the total institutional ownership; VANGUARD GROUP INC, holding 20,279,035 shares of the stock with an approximate value of $183.73 million in PACB stocks shares; and BLACKROCK INC., currently with $167.93 million in PACB stock with ownership of nearly 3.5% of the company’s market capitalization.
Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 114 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 40,862,324 shares. Additionally, 109 investors decreased positions by around 33,447,118 shares, while 47 investors held positions by with 152,933,306 shares. The mentioned changes placed institutional holdings at 227,242,748 shares, according to the latest SEC report filing. PACB stock had 48 new institutional investments in for a total of 30,326,223 shares, while 30 institutional investors sold positions of 7,008,443 shares during the same period.